DK1305319T3 - 4-phenyl-pyridinderivater som neurokinin-1-receptorantagonister - Google Patents

4-phenyl-pyridinderivater som neurokinin-1-receptorantagonister

Info

Publication number
DK1305319T3
DK1305319T3 DK01960529T DK01960529T DK1305319T3 DK 1305319 T3 DK1305319 T3 DK 1305319T3 DK 01960529 T DK01960529 T DK 01960529T DK 01960529 T DK01960529 T DK 01960529T DK 1305319 T3 DK1305319 T3 DK 1305319T3
Authority
DK
Denmark
Prior art keywords
neurokinin
phenyl
receptor antagonists
pyridine derivatives
pyridine
Prior art date
Application number
DK01960529T
Other languages
English (en)
Inventor
Torsten Hoffmann
Patrick Schnider
Heinz Stadler
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of DK1305319T3 publication Critical patent/DK1305319T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
DK01960529T 2000-07-24 2001-07-20 4-phenyl-pyridinderivater som neurokinin-1-receptorantagonister DK1305319T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP00115846 2000-07-24

Publications (1)

Publication Number Publication Date
DK1305319T3 true DK1305319T3 (da) 2006-08-14

Family

ID=8169331

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01960529T DK1305319T3 (da) 2000-07-24 2001-07-20 4-phenyl-pyridinderivater som neurokinin-1-receptorantagonister

Country Status (38)

Country Link
US (2) US6576762B2 (da)
EP (1) EP1305319B1 (da)
JP (1) JP4118673B2 (da)
KR (1) KR100527214B1 (da)
CN (1) CN1192032C (da)
AR (1) AR029875A1 (da)
AT (1) ATE322496T1 (da)
AU (2) AU8200501A (da)
BR (1) BR0112695A (da)
CA (1) CA2416874C (da)
CY (1) CY1106113T1 (da)
CZ (1) CZ2003528A3 (da)
DE (1) DE60118569T2 (da)
DK (1) DK1305319T3 (da)
EC (1) ECSP034446A (da)
ES (1) ES2260265T3 (da)
GT (1) GT200100148A (da)
HK (1) HK1058360A1 (da)
HR (1) HRP20030031A2 (da)
HU (1) HU229231B1 (da)
IL (2) IL153837A0 (da)
JO (1) JO2321B1 (da)
MA (1) MA26933A1 (da)
MX (1) MXPA03000367A (da)
MY (1) MY129224A (da)
NO (1) NO20030353D0 (da)
NZ (1) NZ523452A (da)
PA (1) PA8522801A1 (da)
PE (1) PE20020258A1 (da)
PL (1) PL366173A1 (da)
PT (1) PT1305319E (da)
RU (1) RU2276139C2 (da)
SI (1) SI1305319T1 (da)
TW (1) TWI287003B (da)
UY (1) UY26851A1 (da)
WO (1) WO2002008232A1 (da)
YU (1) YU2803A (da)
ZA (1) ZA200300219B (da)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR200302077T4 (tr) * 1999-11-29 2004-01-21 F. Hoffmann-La Roche Ag 2-(3,5-Bis-Trifluorometil-fenil)-N-metil-N- (6-morfonil-4-il-4-O-tolil-piridin-3-il)- izobütiramit
ES2307925T3 (es) 2002-04-26 2008-12-01 Eli Lilly And Company Antagonistas de los receptores de la taquiquinina.
EA007720B1 (ru) 2002-04-26 2006-12-29 Эли Лилли Энд Компани Производные триазола в качестве антагонистов рецептора тахикинина
AU2003300018A1 (en) * 2002-10-11 2004-05-04 Bristol-Myers Squibb Company Process for the preparation of tri-nitrogen containing heteroaryl-diamine derivatives useful as pharmaceutical agents and methods of producing pharmaceutical agents
WO2005000821A1 (en) * 2003-06-12 2005-01-06 Eli Lilly And Company Tachykinin receptor antagonists
PT1643998E (pt) * 2003-07-03 2007-11-21 Hoffmann La Roche Antagonistas duplos dos receptores de nc1/nc3 para tratar a esquizofrenia
US7288658B2 (en) * 2003-07-15 2007-10-30 Hoffmann-La Roche Inc. Process for preparation of pyridine derivatives
CN1984891B (zh) 2004-07-06 2012-08-08 弗·哈夫曼-拉罗切有限公司 用作合成nk-1受体拮抗剂的中间体的甲酰胺吡啶衍生物的制备方法
US20060030600A1 (en) * 2004-08-06 2006-02-09 Patrick Schnider Dual NK1/NK3 receptor antagonists for the treatment of schizophrenia
US20080045610A1 (en) * 2004-09-23 2008-02-21 Alexander Michalow Methods for regulating neurotransmitter systems by inducing counteradaptations
AU2005286733B2 (en) * 2004-09-23 2009-11-05 Alexander Michalow Methods for regulating neurotransmitter systems by inducing counteradaptations
BRPI0606187A2 (pt) 2005-02-25 2009-06-09 Hoffmann La Roche comprimidos com capacidade de dispersão da substáncia do fármaco melhorada
US8067662B2 (en) 2009-04-01 2011-11-29 Aalnex, Inc. Systems and methods for wound protection and exudate management
US7816577B2 (en) 2006-02-13 2010-10-19 Aalnex, Inc. Wound shield
ES2328185T3 (es) 2006-05-31 2009-11-10 F. Hoffmann-La Roche Ag Derivados de aril-4-etinil-isoxazol.
KR20090112722A (ko) 2007-01-24 2009-10-28 글락소 그룹 리미티드 3,5-디아미노-6-(2,3-디클로로페닐)-1,2,4-트리아진 또는 ｒ(-)-2,4-디아미노-5-(2,3-디클로로페닐)-6-플루오로메틸 피리미딘 및 ｎｋ1을 포함하는 제약 조성물
GB0808747D0 (en) * 2008-05-14 2008-06-18 Glaxo Wellcome Mfg Pte Ltd Novel compounds
US8426450B1 (en) * 2011-11-29 2013-04-23 Helsinn Healthcare Sa Substituted 4-phenyl pyridines having anti-emetic effect
CA2930008A1 (en) 2013-11-08 2015-05-14 Kissei Pharmaceutical Co., Ltd. Carboxymethyl piperidine derivative
TWI649307B (zh) 2014-05-07 2019-02-01 日商橘生藥品工業股份有限公司 Cyclohexylpyridine derivative
WO2016149324A1 (en) 2015-03-16 2016-09-22 Vanderbilt University Negative allosteric modulators of metabotropic glutamate receptor 2
US11324832B2 (en) * 2015-12-22 2022-05-10 Endosome Therapeutics, Inc. Tripartite modulators of endosomal G protein-coupled receptors
RU2020131446A (ru) 2018-02-26 2022-03-28 Оспедале Сан Раффаэле С.Р.Л. Антагонисты nk-1 для применения в лечении глазной боли

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL111960A (en) 1993-12-17 1999-12-22 Merck & Co Inc Morpholines and thiomorpholines their preparation and pharmaceutical compositions containing them
PL181214B1 (pl) 1993-12-29 2001-06-29 Merck Sharp & Dohme Podstawione związki morfolinowe, sposób ich wytwarzania oraz zawierające je kompozycje farmaceutyczne
IL112778A0 (en) 1994-03-04 1995-05-26 Merck & Co Inc Substituted heterocycles, their preparation and pharmaceutical compositions containing them
US5972938A (en) 1997-12-01 1999-10-26 Merck & Co., Inc. Method for treating or preventing psychoimmunological disorders
KR20010041991A (ko) 1998-03-19 2001-05-25 다케다 야쿠힌 고교 가부시키가이샤 복소환식 화합물, 그의 제조법 및 타키키닌 수용체길항약으로서의 용도
JPH11322748A (ja) * 1998-03-19 1999-11-24 Takeda Chem Ind Ltd 複素環化合物、その製造法および用途
CZ20013047A3 (cs) * 1999-02-24 2002-02-13 F. Hoffmann-La Roche Ag 3-Fenylpyridinové deriváty a jejich pouľití jako antagonisty NK-1 receptorů
ES2226622T3 (es) 1999-02-24 2005-04-01 F. Hoffmann-La Roche Ag Derivados de 4-fenil piridina y su empleo como antagonistas del receptor nk-1.
JP4070957B2 (ja) * 1999-02-24 2008-04-02 エフ．ホフマン−ラ ロシュ アーゲー フェニルおよびピリジニル誘導体
US6291465B1 (en) * 1999-03-09 2001-09-18 Hoffmann-La Roche Inc. Biphenyl derivatives
TR200302077T4 (tr) * 1999-11-29 2004-01-21 F. Hoffmann-La Roche Ag 2-(3,5-Bis-Trifluorometil-fenil)-N-metil-N- (6-morfonil-4-il-4-O-tolil-piridin-3-il)- izobütiramit
US6303790B1 (en) * 1999-11-29 2001-10-16 Hoffman-La Roche Inc. Process for the preparation of pyridine derivatives
CZ303639B6 (cs) * 2000-07-14 2013-01-23 F. Hoffmann-La Roche Ag N-Oxid derivátu 4-fenylpyridinu, zpusob jeho prípravy a lécivo s jeho obsahem

Also Published As

Publication number Publication date
SI1305319T1 (sl) 2006-08-31
AR029875A1 (es) 2003-07-16
CA2416874C (en) 2011-01-18
PE20020258A1 (es) 2002-04-02
ATE322496T1 (de) 2006-04-15
AU2001282005B2 (en) 2006-10-19
CZ2003528A3 (cs) 2003-09-17
EP1305319A1 (en) 2003-05-02
HRP20030031A2 (en) 2004-02-29
HK1058360A1 (en) 2004-05-14
RU2276139C2 (ru) 2006-05-10
CA2416874A1 (en) 2002-01-31
JP2004504400A (ja) 2004-02-12
AU8200501A (en) 2002-02-05
ES2260265T3 (es) 2006-11-01
GT200100148A (es) 2002-05-16
MY129224A (en) 2007-03-30
CN1192032C (zh) 2005-03-09
ECSP034446A (es) 2003-03-10
PA8522801A1 (es) 2002-09-30
UY26851A1 (es) 2002-01-31
KR20030015898A (ko) 2003-02-25
PL366173A1 (en) 2005-01-24
MA26933A1 (fr) 2004-12-20
EP1305319B1 (en) 2006-04-05
CN1444589A (zh) 2003-09-24
NO20030353L (no) 2003-01-23
DE60118569D1 (de) 2006-05-18
CY1106113T1 (el) 2011-06-08
TWI287003B (en) 2007-09-21
HU229231B1 (en) 2013-09-30
US20020038030A1 (en) 2002-03-28
KR100527214B1 (ko) 2005-11-08
US6576762B2 (en) 2003-06-10
NO20030353D0 (no) 2003-01-23
WO2002008232A1 (en) 2002-01-31
NZ523452A (en) 2004-07-30
HUP0301272A2 (hu) 2003-08-28
IL153837A0 (en) 2003-07-31
JO2321B1 (en) 2005-09-12
BR0112695A (pt) 2003-04-22
ZA200300219B (en) 2004-04-08
PT1305319E (pt) 2006-08-31
IL153837A (en) 2008-06-05
MXPA03000367A (es) 2003-05-27
US20030130508A1 (en) 2003-07-10
YU2803A (sh) 2006-01-16
US6624176B2 (en) 2003-09-23
DE60118569T2 (de) 2007-02-15
JP4118673B2 (ja) 2008-07-16

Similar Documents

Publication Publication Date Title
DK1309559T3 (da) 4-phenyl-pyridinderivater som neurokinin-1-receptorantagonister
DK1305319T3 (da) 4-phenyl-pyridinderivater som neurokinin-1-receptorantagonister
DK1349839T3 (da) Phenylethenyl- eller phenylethinylderivater som glutamatraceptorantagonister
DK1571145T3 (da) Substitueret piperidinforbindelser til anvendelse som H3 histaminreceptor-antagonister
DK1501809T3 (da) Trizolderivater som tachykininreceptorantagonister
NO20040028L (no) Substituerte anilinske piperidiner som MCH-selektive antagonister
DK1562595T3 (da) Diarylethere som opioidreceptorantagonister
NO20030471D0 (no) Karboksamidforbindelser og deres anvendelse som antagonister for en 11CBY-reseptor
NO20032142L (no) Substituerte 2-fenylaminoimidazolin-fenylketon-derivater som IP-antagonister
NO20021459D0 (no) Piperazin-derivater som 5-HT1B-antagonister
DK1360184T3 (da) Piperidinderivater som neurokinin-1-antagonister
NO20025136L (no) Cykloheksylaminderivat som subtype selektive NMDA- reseptorantagonister
NO20044373L (no) Azetidinderivater som CCR-3-reseptorantagonister
NO20021251D0 (no) Tienoisoksazolyl- og tienylpyrrazolyl-fenoksysubstituerte propylderivater anvendelige som D4antagonister
DK1176144T3 (da) Nye N-triazolylmethyl-piperazinderivater som neurokininreceptor-antagonister
NO20014356D0 (no) Bifenylderivater som antagonister av neurokinin-1 reseptoren
DK1261588T3 (da) Imidazolforbindelser som alfa2-adrenoceptorantagonister
DK1171419T3 (da) Biphenylderivater som antagonister til Neurokinin-1-receptoren
SE0003996D0 (sv) Receptorantagonister
DK1289955T3 (da) Piperidiner til anvendelse som orexinreceptorantagonister
DK1077942T3 (da) Carboxysubstituerede carboxamidderivater som tachykininreceptorantagonister